Vaxart/VXRT

$0.91

-12.49%
-
1D1W1MYTD1YMAX

About Vaxart

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.

Ticker

VXRT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Finney

Employees

109

Headquarters

South san francisco, United States
Website
vaxart.com

Vaxart Metrics

BasicAdvanced
$180.82M
Market cap
-
P/E ratio
-$0.58
EPS
0.60
Beta
-
Dividend rate
$180.82M
0.59872
$1.59
$0.53
2.15M
3.318
4.538
11.117
-67.13%
-97.94%
-77.06%
24.504
2.761
3.69
6,796.26%
30.84%
22.18%

What the Analysts think about Vaxart

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 2 analysts.
449.45% upside
High $8.00
Low $2.00
$0.91
Current price
$5.00
Average price target

Vaxart Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-540.62% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$3.2M
52.38%
Net income
$-17.3M
-0.57%
Profit margin
-540.62%
-34.75%

Vaxart Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.24%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.19
-$0.16
-$0.11
-$0.12
-
Expected
-$0.19
-$0.18
-$0.18
-$0.15
-$0.14
Surprise
1.79%
-11.11%
-37.74%
-17.24%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Vaxart stock?

Vaxart (VXRT) has a market cap of $180.82M as of April 14, 2024.

What is the P/E ratio for Vaxart stock?

The price to earnings (P/E) ratio for Vaxart (VXRT) stock is 0 as of April 14, 2024.

Does Vaxart stock pay dividends?

No, Vaxart (VXRT) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Vaxart dividend payment date?

Vaxart (VXRT) stock does not pay dividends to its shareholders.

What is the beta indicator for Vaxart?

Vaxart (VXRT) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Vaxart stock price target?

The target price for Vaxart (VXRT) stock is $5, which is 449.45% above the current price of $0.91. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Vaxart stock

Buy or sell Vaxart stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing